SCHEMBL19853858

SCHEMBL19853858

C=C(CO)C(=O)OCCOc1ccc(-c2ccc(-c3ccc(C4CCC(CCCCCCC)CC4)cc3)cc2)cc1OCCOC(=O)C(=C)CO

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 3/20 0.37
CYP2C9 P11712 1/20 0.35
PTPN1 P18031 1/20 0.35
PTPN6 P29350 1/20 0.35
PPARG P37231 5/20 0.35
DGAT1 O75907 1/20 0.35
FPR2 P25090 1/20 0.35
MAPT P10636 2/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
P2RY14 Q15391 1/20 0.33
SPHK1 Q9NYA1 2/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
PPARA Q07869 1/20 0.33
GAA P10253 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19853843 0.99 CYP2C9 (0.36) PTPN11CYP2C9PTPN1PTPN6PPARG
SCHEMBL19855086 0.99 CYP2C9 (0.36) PTPN11CYP2C9PTPN1PTPN6PPARG
SCHEMBL20407651 0.96 FPR2 (0.35) PTPN11CYP2C9PTPN1PTPN6PPARG
SCHEMBL19853861 0.94 PTPN11 (0.33) PTPN11CYP2C9PTPN1PTPN6PPARG
SCHEMBL20313592 0.93 CYP2C9 (0.36) PTPN11CYP2C9PTPN1PTPN6PPARG
SCHEMBL19853859 0.93 CYP2C9 (0.36) PTPN11CYP2C9PTPN1PTPN6PPARG
SCHEMBL19853855 0.93 PDE4A (0.39) CYP2C9PPARGMAPTALDH1A1LMNA
SCHEMBL19853851 0.92 FFAR4 (0.33) PTPN11CYP2C9PPARGDGAT1FPR2
SCHEMBL19722369 0.92 RARB (0.36) PTPN11CYP2C9PTPN1PTPN6PPARG
SCHEMBL19853846 0.92 CYP2C9 (0.37) PTPN11CYP2C9PTPN1PTPN6PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210214615-A1 LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT JNC CORPORATION (JP) 2021-07-15 US disclosed
EP-3351525-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC Corporation (JP) 2018-07-25 EP disclosed
US-20180179443-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-06-28 US disclosed
US-20180179443-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-06-28 US disclosed
WO-2018025974-A1 LIQUID-CRYSTAL DISPLAY ELEMENT AND DISPLAY DEVICE JNC株式会社 2018-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180179443-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE C1S, CCND1, C5 PTPN11 3649/4885CYP2C9 3375/4885PTPN1 1871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.